ALIKO SCIENTIFIC
Press Releases

Financial Information
The Ikonisys Group Unveils its New Vision and Strategy Under the Brand ALIKO SCIENTIFIC
04/12/2024
The Ikonisys Group Unveils its New Vision and Strategy Under the Brand ALIKO SCIENTIFIC
Ikonisys Announces the Launch of Ikoniscope Max in Europe at the 36th European Congress of Pathology in Florence
09/09/2024
Ikonisys Announces the Launch of Ikoniscope Max in Europe at the 36th European Congress of Pathology in Florence
Terms and Conditions of availability of preparatory documents for the General Meeting of September 25, 2024
04/09/2024
Terms and Conditions of availability of preparatory documents for the General Meeting of September 25, 2024
Ikonisys completed a capital increase through a private placement
15/08/2024
Ikonisys completed a capital increase through a private placement
Ikonisys completed a capital increase through a private placement with CC Holding Srl
18/07/2024
Ikonisys completed a capital increase through a private placement with CC Holding Srl
Ikonisys announces that Hospitex International signed supply contracts in Italy marking growth potential for the Group
09/07/2024
Ikonisys announces that Hospitex International signed supply contracts in Italy marking growth potential for the Group
Ikonisys: the 2023 Annual Report is now available
08/07/2024
Ikonisys: the 2023 Annual Report is now available
Ikonisys reports its Full-Year Financial Results for 2023 and provides an update on its latest developments
02/07/2024
Ikonisys reports its Full-Year Financial Results for 2023 and provides an update on its latest developments
Ikonisys and Ulisse Biomed Announce Strategic Partnership to Support Innovation in Cancer Diagnostics
11/06/2024
Ikonisys and Ulisse Biomed Announce Strategic Partnership to Support Innovation in Cancer Diagnostics
Ikonisys closes capital increase through a private placement to further accelerate its commercial development
03/06/2024
Ikonisys closes capital increase through a private placement to further accelerate its commercial development
Ikonisys Introduces New Website to Highlight Advantages of FISH Technology and Total Automation in Healthcare
30/05/2024
Ikonisys Introduces New Website to Highlight Advantages of FISH Technology and Total Automation in Healthcare
Ikonisys announces postponement of the publication of its 2023 annual financial report
24/05/2024
Ikonisys announces postponement of the publication of its 2023 annual financial report
Ikonisys: Hospitex Expands in Ukraine through a Partnership with Diagen LLC to Fight Cancer
21/05/2024
Ikonisys: Hospitex Expands in Ukraine through a Partnership with Diagen LLC to Fight Cancer
Ikonisys: Hospitex to obtain international patent for the BLOCKfast cyto-inclusion kit
15/05/2024
Ikonisys: Hospitex to obtain international patent for the BLOCKfast cyto-inclusion kit
Ikonisys announces the postponement of the publication of its annual financial report
30/04/2024
Ikonisys announces the postponement of the publication of its annual financial report
Ikonisys: Hospitex International to partner with Allianz Value for first large-scale screening program dedicated to urinary tract oncology diagnostics in Italy
29/02/2024
Ikonisys: Hospitex International to partner with Allianz Value for first large-scale screening program dedicated to urinary tract oncology diagnostics in Italy
Ikonisys announces that Hospitex International won the public tender of the prestigious U.O.C. Pathological Anatomy of Ragusa
19/02/2024
Ikonisys announces that Hospitex International won the public tender of the prestigious U.O.C. Pathological Anatomy of Ragusa
Ikonisys: new production record for Hospitex International
02/01/2024
Ikonisys: new production record for Hospitex International
Ikonisys announces the completion of a private placement to speed up growth following recent pivotal deals
28/12/2023
Ikonisys announces the completion of a private placement to speed up growth following recent pivotal deals
Ikonisys announces a partnership between Hospitex International and the Pathologists Beyond Borders Association
15/12/2023
Ikonisys announces a partnership between Hospitex International and the Pathologists Beyond Borders Association
Ikonisys to Acquire Hospitex International and Become an Integrated Cancer Diagnostic Leader
30/11/2023
Ikonisys to Acquire Hospitex International and Become an Integrated Cancer Diagnostic Leader
Ikonisys and Biocare Medical Forge Alliance: Amplifying Global FISH Diagnostics with Advanced Fluorescent Scopes
31/10/2023
Ikonisys and Biocare Medical Forge Alliance: Amplifying Global FISH Diagnostics with Advanced Fluorescent Scopes
Ikonisys publishes its 2023 half-year financial results and reviews its operational and strategic deployments
30/10/2023
Ikonisys publishes its 2023 half-year financial results and reviews its operational and strategic deployments
Ikonisys successfully completed its ISO certification reaffirming its ability to continuously meet quality international standard requirements
16/10/2023
Ikonisys successfully completed its ISO certification reaffirming its ability to continuously meet quality international standard requirements
Successful study in collaboration with the Neag Cancer Center of UConn School of Medicine demonstrates the power of the Ikoniscope platform for detection of extremely rare cells in the field of immuno-oncology
10/10/2023
Successful study in collaboration with the Neag Cancer Center of UConn School of Medicine demonstrates the power of the Ikoniscope platform for detection of extremely rare cells in the field of immuno-oncology
Ikonisys announces the completion of new financing via the issuance of a €0.5m private Note
03/08/2023
Ikonisys announces the completion of new financing via the issuance of a €0.5m private Note
Increase in the resources allocated to the liquidity contract entrusted to Invest Securities
31/07/2023
Increase in the resources allocated to the liquidity contract entrusted to Invest Securities
Ikonisys presents an update of its global activity in the context of its recent technological and commercial milestones
31/07/2023
Ikonisys presents an update of its global activity in the context of its recent technological and commercial milestones
Half-yearly report on the Ikonisys liquidity contract at 30/06/2023
26/07/2023
Half-yearly report on the Ikonisys liquidity contract at 30/06/2023
Ikonisys announces the results of its Ordinary Annual and Extraordinary General Meeting of June 28, 2023
30/06/2023
Ikonisys announces the results of its Ordinary Annual and Extraordinary General Meeting of June 28, 2023
Ikonisys announces the first sale of the Ikoniscope20max solution
21/06/2023
Ikonisys announces the first sale of the Ikoniscope20max solution
Ikonisys announces the completion of a private placement to accelerate its commercial development
15/06/2023
Ikonisys announces the completion of a private placement to accelerate its commercial development
Ikonisys publishes its Full-Year Financial Results for 2022 and provides an update on its latest developments
29/04/2023
Ikonisys publishes its Full-Year Financial Results for 2022 and provides an update on its latest developments
Ikonisys and Integrated Gulf Biosystems Group enter into Distribution Collaboration for Distribution of the Ikoniscope20 System in the Middle East Market
30/01/2023
Ikonisys and Integrated Gulf Biosystems Group enter into Distribution Collaboration for Distribution of the Ikoniscope20 System in the Middle East Market
Ikonisys announces the launch of its instrument for high-volume customers, the Ikoniscope20max
14/11/2022
Ikonisys announces the launch of its instrument for high-volume customers, the Ikoniscope20max
Ikonisys publishes its 2022 half-year financial results and reviews its operational deployments
27/10/2022
Ikonisys publishes its 2022 half-year financial results and reviews its operational deployments
Ikonisys has signed a financing agreement of up to €5.1m of aggregate principal amount to continue its commercial and development strategy and has drawn down a first tranche
05/10/2022
Ikonisys has signed a financing agreement of up to €5.1m of aggregate principal amount to continue its commercial and development strategy and has drawn down a first tranche
Ikonisys announces the installation of the Ikoniscope20 solution at a US leading urology laboratory
26/09/2022
Ikonisys announces the installation of the Ikoniscope20 solution at a US leading urology laboratory
Ikonisys and Negma Group announce the end of their financing agreement
20/09/2022
Ikonisys and Negma Group announce the end of their financing agreement
Ikonisys announces the start of a Distribution Collaboration with BioVendor Laboratory Medicine for Distribution of the Ikoniscope20 System in the Eastern European Market
13/09/2022
Ikonisys announces the start of a Distribution Collaboration with BioVendor Laboratory Medicine for Distribution of the Ikoniscope20 System in the Eastern European Market
Ikonisys reinforces its strategic collaboration with Empire Genomics following excellent results of optimized reagents in detection of bladder cancer cells
26/07/2022
Ikonisys reinforces its strategic collaboration with Empire Genomics following excellent results of optimized reagents in detection of bladder cancer cells
Ikonisys announces the first sale of the Ikoniscope20 solution including the newly added reagents to Comprehensive Urology
22/06/2022
Ikonisys announces the first sale of the Ikoniscope20 solution including the newly added reagents to Comprehensive Urology
Ikonisys signs contract and initiates research activities with Politecnico di Milano, a world leading public scientific-technological university in the field of computer science and bioengineering
24/05/2022
Ikonisys signs contract and initiates research activities with Politecnico di Milano, a world leading public scientific-technological university in the field of computer science and bioengineering
IKONISYS PARTNERS WITH EVOSCIENCES LEASING TO SUPPORT THE COMMERCIAL EXPANSION IN EUROPE AND THE USA OF THE IKONISCOPE20
12/05/2022
IKONISYS PARTNERS WITH EVOSCIENCES LEASING TO SUPPORT THE COMMERCIAL EXPANSION IN EUROPE AND THE USA OF THE IKONISCOPE20
Ikonisys has signed a financing agreement of up to €6m of aggregate nominal amount to continue the commercial roll-out map
04/05/2022
Ikonisys has signed a financing agreement of up to €6m of aggregate nominal amount to continue the commercial roll-out map
Ikonisys publishes its Full-Year Financial Results for 2021 and provides an update on its latest developments
29/04/2022
Ikonisys publishes its Full-Year Financial Results for 2021 and provides an update on its latest developments
Ikonisys announces its participation in the Investor Access forum
29/03/2022
Ikonisys announces its participation in the Investor Access forum
The Ikoniscope20 preliminary results obtained with University of Connecticut School of Medicine (Neag Cancer Center of UConn) in detecting rare cells surpass the standards of test in immuno-oncology
16/02/2022
The Ikoniscope20 preliminary results obtained with University of Connecticut School of Medicine (Neag Cancer Center of UConn) in detecting rare cells surpass the standards of test in immuno-oncology
Ikonisys announces the successfull installation of the Ikoniscope20 at TomaLab, one of the largest genetic laboratories in Italy
07/02/2022
Ikonisys announces the successfull installation of the Ikoniscope20 at TomaLab, one of the largest genetic laboratories in Italy
Ikonisys sa announces the appointment of Gabriel Plan as France sales director
01/02/2022
Ikonisys sa announces the appointment of Gabriel Plan as France sales director
Ikonisys announces the initation of coverage of its stock by Sphene Capital
26/01/2022
Ikonisys announces the initation of coverage of its stock by Sphene Capital
Ikonisys publishes its half-year financial results for 2021 and provides an update on its developments since its IPO
29/10/2021
Ikonisys publishes its half-year financial results for 2021 and provides an update on its developments since its IPO
Ikonisys sa welcomes us sales director, accelerating its growth and expansion plans in the USA
30/09/2021
Ikonisys sa welcomes us sales director, accelerating its growth and expansion plans in the USA
Initial results of a study, in collaboration with the Uconn School of Medicine, highlight the potential of Ikonisys’ cellbased diagnostic platform in immuno-oncology
06/09/2021
Initial results of a study, in collaboration with the Uconn School of Medicine, highlight the potential of Ikonisys’ cellbased diagnostic platform in immuno-oncology
Success of Ikonisys’ initial public offering on Euronext growth® Paris
13/07/2021
Success of Ikonisys’ initial public offering on Euronext growth® Paris

Get in touch

Come and visit our quarters or simply send us an email anytime you want. We are open to all requests.
Address
5 Science Park, New Haven, Connecticut
06511 - USA
Call us
+1.203.776.0791


Email
corporate@ikonisys.com


https://alikoscientific.com/wp-content/uploads/2024/12/logo-aliko-new-version-1.png

ALIKO

IKONISYS

HOSPITEX

CONTACTS

Ikonisys, SA
62, rue de Caumartin
75009 Paris
Email: investors@ikonisys.com

Copyright by Ikonisys SA. All rights reserved.